Market News How it works Learn FAQ
| RCT 0.0923 21.29% | NU 12.5021 -17.53% | EWZ 34.02 -20.12% | BBD 2.877 -29.31% | TGL 0.2429 9.66% | AZTR 2.05 186.71% | ITUB 7.68 -20.58% | SRTM 0.2775 -35.51% | NVD 3.995 -4.65% | XP 15.4801 -49.10% | WFF 0.089 11.25% | SHFS 0.091 -31.27% | SPCX 149.37 1.27% | SOXL 92.37 10.54% | PBR 22.715 -13.17% | VALE 11.99 -3.31% | CLRO 4.84 48.92% | INTC 91.75 5.51% | GCDT 0.1443 -18.06% | TSLL 10.885 11.53% | NWGL 0.0872 6.34% | NOK 8.715 7.06% | NVDA 216.1126 2.44% | SOXS 46.95 -10.50% | CRWV 56.22 3.66% | BITO 10.695 -1.25% | RWM 14.475 -0.52% | GPUS 0.1858 10.01% | SGRY 23.185 47.21% | TSLG 5.445 11.81% | ABEV 2.805 -15.00% | JBLU 2.285 -12.95% | IREN 26.025 4.50% | INTR 4.595 -36.09% | RBNE 0.1682 -11.47% | QID 14.1701 -2.61% | AAL 12.1792 0.57% | TQQQ 68.8286 3.83% | SBS 4.6303 -27.65% | SPDN 8.485 -0.64% | TSLA 393.84 5.81% | T 20.6998 -1.10% | LUCD 0.538 30.90% | SID 0.9075 -23.09% | WULF 12.3201 8.83% | XTND 2.2899 29.37% | NFLX 63.005 -4.32% | CIFR 7.885 -0.69% | SQQQ 38.17 -3.81% | RIG 6.555 2.26%
RPRepare Therapeutics Inc. logo

Repare Therapeutics Inc. (RPTX)

NASDAQ Global Select · Currency in USD
$2.65 ▲ +0.00 (+0.00%)
As of Jan 28, 4:00 PM ET. Market open.

Summary

Previous Close
$2.65
Open
$2.65
Day's Range
$2.65 – $2.65
52 Week Range
$0.89 – $2.66
Volume
1,167,676
Avg. Volume
1,175,734
Market Cap
$114.24M
Beta (5Y Monthly)
0.96
PE Ratio (TTM)
--
EPS (TTM)
-$0.31
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$16.00

Profile: Repare Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
129
CEO
Steve Forte

Repare Therapeutics Inc. is a precision oncology biopharmaceutical company in the clinical stage, focused on discovering and developing innovative therapies. Operating across Canada and the United States, the company leverages a synthetic lethality approach to identify new treatments. Central to their efforts is the proprietary, genome-wide, and CRISPR-enabled SNIPRx platform, which systematically uncovers and advances highly targeted cancer medicines.

Earnings

DateEst.Actual
Mar 2, 2026-$0.29-$0.67Miss
Nov 14, 2025-$0.35$0.08Beat
Aug 8, 2025-$0.56-$0.39Beat
May 13, 2025-$0.65-$0.71Miss
Mar 3, 2025-$0.77-$0.67Beat
Nov 7, 2024-$0.83-$0.81Beat

Analyst view

Consensus price target
$16.00 ▲ +503.8%
Range $3.00 – $30.00
Rating: Buy
Buy 78% · Hold 22% · Sell -0%

Get free alerts on RPTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.